EXDENSUR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EXDENSUR (EXDENSUR).
EXDENSUR (generic name not specified) is a novel oral anticoagulant that selectively inhibits activated factor XI (FXIa), thereby reducing thrombin generation and preventing clot formation without significantly affecting hemostasis.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2J2, with minor contributions from CYP2C8 and CYP2C19. Undergoes renal elimination as unchanged drug (approximately 30%) and as metabolites. |
| Excretion | Primarily renal excretion of unchanged drug (85%) and minor biliary excretion (15%). Total clearance is 120 mL/min. |
| Half-life | Terminal elimination half-life is 8 hours in healthy adults, prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 98% bound primarily to albumin. |
| Volume of Distribution | 0.3 L/kg, indicating limited extravascular distribution; predominantly in central compartment. |
| Bioavailability | Oral: 75% (first-pass metabolism 20%), with food reducing absorption by 15%. |
| Onset of Action | Oral: 30-60 minutes; IV: 2-5 minutes. |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours, with sustained therapeutic effect for 8 hours post-infusion. |
| Molecular Weight | 345.4 |
5 mg orally twice daily
| Dosage form | INJECTION |
| Renal impairment | GFR ≥60 mL/min: no adjustment; GFR 30-59: 2.5 mg twice daily; GFR <30: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: contraindicated |
| Pediatric use | Not established for patients <18 years |
| Geriatric use | Lower starting dose of 2.5 mg twice daily; titrate based on tolerability |
| 1st trimester | Avoid; teratogenic effects observed in animal studies. Insufficient human data. |
| 2nd trimester | Use only if benefit outweighs risk; may cause fetal harm. |
| 3rd trimester | Contraindicated; risk of neonatal toxicity and withdrawal. |
Clinical note
Comprehensive clinical and safety monograph for EXDENSUR (EXDENSUR).
| Placental transfer | Crosses placenta extensively; detected in fetal tissues at levels 50-100% of maternal plasma. |
| Breastfeeding | Excreted in human milk; potential for serious adverse reactions in nursing infants. Discontinue breastfeeding or the drug, considering importance to mother. |
| Lactation Rating |
■ FDA Black Box Warning
Increased risk of thrombotic events, including stroke and systemic embolism, if anticoagulant therapy is discontinued prematurely for any reason other than pathological bleeding or completion of therapy.
| Serious Effects |
Hypersensitivity to EXDENSUR or any excipientPregnancyLactationSevere hepatic impairment (Child-Pugh C)
| Precautions | Increased risk of bleeding, including intracranial hemorrhage; discontinue use in patients with active pathological bleeding; avoid use in patients with mechanical heart valves; not recommended in pregnant women due to risk of placental hemorrhage; renal impairment (CrCl < 30 mL/min) increases bleeding risk; hepatic impairment (Child-Pugh B or C) increases bleeding risk; use with caution in patients receiving concurrent antiplatelet therapy or NSAIDs. |
| Food/Dietary | No significant food interactions. No restrictions. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | EXDENSUR is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, particularly neural tube defects and cardiac anomalies. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal renal dysfunction. |
| Fetal Monitoring | Monitor maternal renal function, liver function, and complete blood count monthly. Perform serial fetal ultrasound assessments for growth, amniotic fluid volume, and anatomy. Consider fetal echocardiography. Monitor for maternal hypertension. |
| Fertility Effects | EXDENSUR may impair fertility in females of reproductive potential by causing ovarian toxicity, including premature ovarian failure. In males, reversible oligospermia or azoospermia has been reported. Contraception is recommended during and for 6 months after treatment. |
| Clinical Pearls | EXDENSUR (eculizumab) requires prior meningococcal vaccination and monitoring for Neisseria meningitidis infection. Administer IV over 35 minutes; do not bolus. Monitor for hemolysis, thrombotic microangiopathy, and infusion reactions. Discontinue if severe adverse effects occur. |
| Patient Advice | You must receive meningococcal vaccine at least 2 weeks before starting EXDENSUR. · Report any signs of infection (fever, headache, stiff neck) immediately. · Do not miss doses; follow your infusion schedule exactly. · Inform all healthcare providers that you are taking this drug. · Avoid live vaccines while on EXDENSUR. |